Sarcopenia vs body mass index (BMI) as a prognostic biomarker in patients with metastatic clear cell renal cell carcinoma (mCCRCC) in the era of first line immune checkpoint inhibitors (ICIs)

被引：0
|
作者：
La Course, Bryce Douglas
Orcutt, Delaney
Gross, Evan
Fintelmann, Florian J.
Master, Viraj A.
Hall, Evan Thomas
Wrobel, Maria Marta
Psutka, Sarah P.
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Vanderbilt Univ, Nashville, TN USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Div Thorac Imaging & Intervent, Boston, MA USA
[4] Emory Univ, Atlanta, GA USA
[5] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[6] Ludwig Maximilians Univ Munchen, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16515
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EFFECTS OF FIRST-LINE IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA NOT MEETING TRIAL ELIGIBILITY CRITERIA
    Nemoto, Yuki
    Ishihara, Hiroki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    JOURNAL OF UROLOGY, 2022, 207 (05): : E173 - E173
  • [32] Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).
    Nuzzo, Pier Vitale
    Curran, Catherine
    Adib, Elio
    Freeman, Dory
    Nassar, Amin
    Abou Alaiwi, Sarah
    Bakouny, Ziad
    McGregor, Bradley Alexander
    Choueiri, Toni K.
    Jain, Rakesh K.
    McKay, Rana R.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [33] Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
    Graham, Jeffrey
    Wells, Connor
    Dudani, Shaan
    Gan, Chun Loo
    Donskov, Frede
    Lee, Jae-Lyun
    Kollmannsberger, Christian K.
    Pal, Sumanta K.
    Beuselinck, Benoit
    Hansen, Aaron Richard
    North, Scott A.
    Bjarnason, Georg A.
    Agarwal, Neeraj
    Kanesvaran, Ravindran
    Wood, Lori
    Hotte, Sebastien J.
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC)
    Agarwal, Anika
    Modliszewski, Jennifer
    Davey, Lauren
    Reyes-Martinez, Marco
    Runyambo, Daniella
    Corcoran, David
    Dressman, Holly
    George, Daniel J.
    Valdivia, Raphael
    Armstrong, Andrew J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [35] Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma
    Herrmann, Tressie
    Mione, Cecile
    Montoriol, Pierre-Francois
    Molnar, Ioana
    Ginzac, Angeline
    Durando, Xavier
    Mahammedi, Hakim
    ONCOLOGY, 2022, 100 (02) : 114 - 123
  • [36] Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
    Song, Yan
    Du, Chunxia
    Zhang, Wen
    Sun, Yongkun
    Yang, Lin
    Cui, Chengxu
    Chi, Yihebali
    Shou, Jianzhong
    Zhou, Aiping
    Wang, Jinwan
    Sun, Yan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 258.e15 - 258.e22
  • [37] Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma
    Yuki Nemoto
    Hiroki Ishihara
    Kazutaka Nakamura
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Kazunari Tanabe
    Tsunenori Kondo
    Toshio Takagi
    International Urology and Nephrology, 2022, 54 : 47 - 54
  • [38] Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors
    Chahoud, Jad
    Msaouel, Pavlos
    Ross, Jeremy A.
    McCormick, Barrett Z.
    Bathala, Tharakeswara K.
    Gao, Jianjun
    Horn, Robert
    Xiao, Lianchun
    Sircar, Kanishka
    Campbell, Matthew T.
    Shah, Amishi Y.
    Goswami, Sangeeta
    Zurita, Amado J.
    Jonasch, Eric
    Matin, Surena F.
    Wood, Christopher G.
    Karam, Jose A.
    Sharma, Padmanee
    Tannir, Nizar M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (02) : 134.e9 - 134.e16
  • [39] Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma
    Nemoto, Yuki
    Ishihara, Hiroki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (01) : 47 - 54
  • [40] Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).
    Bakouny, Ziad
    Abou Alaiwi, Sarah
    Nassar, Amin
    Steinharter, John A.
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Harshman, Lauren Christine
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
12345